logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

5 Micro and Small-Cap Biotechs Developing Stem Cell Treatments

By  +Follow August 1, 2013 8:43AM
Share:
Tickers Mentioned:

Stem cells have once again flitted through the news cycle, this time as a result of a new and growing industry that has arisen around the use of adult stem cells in cosmetic treatments that purport to both be more effective and less dangerous than traditional procedures such as the infamous and potentially toxic Botox injections.

But the scientific basis for the use of stem cells for cosmetic procedures is entirely tentative. To date, the US Food and Drug Administration has not approved any stem cell-based products for use, aside from a small number of umbilical cord blood-derived treatments for blood cancer as well as hereditary metabolic and autoimmune disorders.

Cosmetic treatments of any variety are subject to far less scrutiny than medical treatments, however, and this is what is currently allowing an increasing amount of doctors throughout the country to charge as much as $30,000 for procedures whose value are more or less unproven from the standpoint of official studies, clinical trials, and peer reviews.

Considering that so few medical products involving stem cells have been approved, a high degree of skepticism should probably be applied to any magical claims about the potential for stem cells to make one look younger, or to otherwise repair one’s perceived cosmetic iniquities. A terrifying article that appeared last December in The Scientific American suffices to support this contention.

But stem cells, whether of the adult of cord-blood variety, are believed to have regenerative properties that could repair all manner of human diseases and conditions, from cardiovascular conditions, to autoimmune diseases. The following five companies are biotechs that are working to ostensibly better the human condition through the use of stem-cell technology, and are all in the midst of clinical trials for various treatments, or on their way to beginning them

Osiris Therapeutics (OSIR) — With a market cap of $377 million, the Columbia, Maryland-based Osiris Therapeutics focuses on the development and marketing of stem cell products to treat serious inflammatory, autoimmune, orthopedic, and cardiovascular conditions. The company’s shares are currently priced at $11.45 and are up over 38 percent over the last six months.

Pluristem (PSTI) — The Israel-based Pluristem develops stem cell therapies from placenta cells for a number of diseases, and is currently preparing for clinical trials for a Peripheral Artery Disease treatment. The company has a market cap of $173.9 million, with shares trading at $2.98, down 7 percent over the past half year.

Cytori Therapeutics (CYTX) — Cytoris Therapeutics uses adult stem cells to develop regenerative therapies for cardiovascular conditions and soft tissue defects. The US company has a market cap of $188.9 million with shares currently priced at $2.82, up 2.5 percent over the last six months.

Neostem (NBS) — The New York, NY-based Neostem owns and operates a number of subsidiaries in the stem-cell based regenerative medicine industry that develop treatments for cardiovascular, autoimmune, and inflammatory conditions. The company is nearing clinical trials for a periodontitis treatment. With a market cap of $117.7 million, shares are currently priced at $7.05, up 10 percent over the past six months, and 17 percent year-to-date.

Advanced Cell Technology ($ACTC) — The Santa Monica, CA-based Advanced Cell Technology uses both adult and embryonic stem cells to develop treatments for retinal, blood, and heart diseases, and has recently initiated two different clinical trials for degenerative retinal disease. With a market cap of $179 million, shares are currently priced at $0.07, down $0.01 over the past six months.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for cytx
Captain Future
23 Oct 14 05:05:10
Maxim complete $CYTX note PT 5.00 (.70) FDA Green-Lights Athena to Move Forward: We See a New Strategy (cont) http://t.co/nJcR7B7xis
Captain Future
23 Oct 14 04:34:20
RT @BlinkX90: $CYTX tiny mkt cap, +$25m cash est, + BARDA contract option value of $20m w 2 more options valued at $45m and $23m http://t.…
Captain Future
23 Oct 14 04:24:15
$CYTX CYTORI THERAPEUTICS JUMPS 70 PCT TO 78 CENTS IN PREMARKET, GETS FDA APPROVAL TO RESUME ATHENA TRIAL ENROLLMENT #stemcells
Gilly
23 Oct 14 04:22:05
$CYTX should be interesting gapping to .78 from .48 on news FDA allows trial to be restarted without limitations
BioBreakout
23 Oct 14 04:18:15
$CYTX Misleading Headline of the Day goes to Cytori Therapeutics... "Receives FDA Approval to Resume ATHENA Trial" http://t.co/R3gOrMqhZw
finsents
23 Oct 14 04:15:09
$CYTX:US #CYTORI THERAPEUTICS INC 23Oct Positive #NewsSentiment http://t.co/3ZuFY3PVLn #NASDAQ
Blink
23 Oct 14 04:00:24
$CYTX tiny mkt cap, +$25m cash est, + BARDA contract option value of $20m w 2 more options valued at $45m and $23m http://t.co/K2ZRjmyLVG
equities.com
23 Oct 14 03:59:32
Cytori Therapeutics Inc (CYTX) Hits New 52-week Low During October 22 Session $cytx http://t.co/p3DjsOy0oR
Blink
23 Oct 14 03:58:06
$CYTX Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment, was over 2, 8/5 when trial halted http://t.co/eNxTTVcCLC
StockKingz
23 Oct 14 03:22:14
Watch List- $rgls $jns $ibio $scty $uvxy $gwph $NXPI $UVXY $cytx $adhd $tsco $yelp $airm $zaza $irbt
Captain Future
23 Oct 14 03:14:00
$CYTX clinical hold gap to close at 2.08 - that near the 200dma 2.14 close yestrday .46 premarket .78 target 2.00+ - #multidayRunner
ChartReaderE
23 Oct 14 03:13:09
I'm now long 1k shares $CYTX @ .77
Captain Future
23 Oct 14 03:11:35
$CYTX up 66% premarket on FDA approval to continue with halted clinical trial - was over $2.00 before in august - could do 200% move easy !
svenmhartke
23 Oct 14 01:11:44
$CYTX Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/4FUIlDxFnn
ThePennyCommand.com
22 Oct 14 22:56:49
http://t.co/rCFETx8Oyc Blade$dream: $CYTX nice move on FDA: Blade$dream http://t.co/aeIOMJSqre http://t.co/rCFETx8Oyc
4-traders.com
22 Oct 14 22:55:34
Cytori Therapeutics : Announces Closing of Financing http://t.co/Sch2nN5OfR $CYTX
4-traders.com
22 Oct 14 22:30:13
Cytori Therapeutics : Reports Dean's Resignation http://t.co/R8ddqBX3WH $CYTX
4-traders.com
22 Oct 14 22:25:27
Cytori Therapeutics : Closes Financing http://t.co/zf9MolxQXQ $CYTX
crawfish_poboy
22 Oct 14 20:46:29
$CYTX possible cheapy long other than that - staying focused with small w/l
Matty Yoakum
22 Oct 14 20:23:25
@StockKingz $CYTX might be one for PM
MAISA
22 Oct 14 17:25:03
$CYTX After Hours: $0.680 +$0.218 (47.09%)
MAISA
22 Oct 14 17:23:26
$CYTX Receives FDA Approval to Resume ATHENA Trial Enrollment
Donnie Miranda
22 Oct 14 17:21:53
RT @Briefingcom: $CYTX: Cytori Therapeutics receives FDA approval to resume ATHENA trial enrollment http://t.co/occpuXOv65
Scalp Trades
22 Oct 14 17:20:50
http://t.co/qy0iEYfRE0 Premarket Trading Ideas for Oct 23rd: $CYTX, $ACTG, $CAKE $CTXS, $CLB, $FTNT, $INFN, $IPCM, $YELP, $PLCM, $TSCO, $XIV
Scott Thomas
22 Oct 14 17:20:35
RT @Briefingcom: $CYTX: Cytori Therapeutics receives FDA approval to resume ATHENA trial enrollment http://t.co/occpuXOv65
Briefing.com
22 Oct 14 17:19:52
$CYTX: Cytori Therapeutics receives FDA approval to resume ATHENA trial enrollment http://t.co/occpuXOv65
ʇɐpıʍdnznʍ
22 Oct 14 17:00:10
RT @Brianwihub: $CYTX FDA approval to resume trials
Brian Welsh
22 Oct 14 16:58:03
$CYTX FDA approval to resume trials
Stock Moo
22 Oct 14 16:54:43
$cytx: Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/1q7LJ8fuh2
Brian Welsh
22 Oct 14 16:51:47
$CYTX on watch in the AM
On Time Picks
22 Oct 14 16:50:55
DewDiligence: FDA allows $CYTX to resume enrollment in ATHENA trials:: DewDiligence http://t.co/yvNmNrcZLB
Russell Barbour
22 Oct 14 16:46:13
RT @BlinkX90: $CYTX this was over 2 in Aug when the trial was halted decent cash too cardio trial
Jason Mertz
22 Oct 14 16:15:00
@johnwelshtrades $CYTX.
super call
22 Oct 14 16:14:40
$CYTX conversion at $0.52 and warrants at $0.57 http://t.co/I9PBrV7wwC
Weedhoppa
22 Oct 14 16:13:52
$CYTX 16% of float is short...I dont think they are going to be too happy tomorrow
Stan
22 Oct 14 16:10:08
RT @BlinkX90: $CYTX this was over 2 in Aug when the trial was halted decent cash too cardio trial
TMcNasty
22 Oct 14 16:07:41
RT @BlinkX90: $CYTX this was over 2 in Aug when the trial was halted decent cash too cardio trial. //Ebola related? ;)
@super_trades
22 Oct 14 16:06:15
RT @BlinkX90: $CYTX this was over 2 in Aug when the trial was halted decent cash too cardio trial
Blink
22 Oct 14 15:59:03
$CYTX this was over 2 in Aug when the trial was halted decent cash too cardio trial
Blink
22 Oct 14 15:58:29
$CYTX Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/eNxTTVcCLC
Cytori IR
22 Oct 14 15:55:33
$CYTX Receives FDA Approval to Resume ATHENA Trial Enrollment [http://t.co/WFdODjrg3I]
Stock Moo
22 Oct 14 15:54:44
$cytx: Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/wfpL9yk9TX
Scalp Trades
22 Oct 14 15:42:15
$Cytx fda approval up 65%
mHealth Reporter
22 Oct 14 15:21:40
RT @BV_Healthcare: $CYTX Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment.. http://t.co/oj5j0ZQtqO
dj
22 Oct 14 15:20:43
? RT @VisualStockRSRC: $CYTX - Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/nEtiaJUHpX
Pzaa...Guy
22 Oct 14 15:20:11
$CYTX - Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/xDOORhNhmM
StockNews
22 Oct 14 15:20:08
$CYTX - Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/7rhaRXCB1f
Stocks News&Markets
22 Oct 14 15:20:07
$CYTX - Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/R0ZdBtz995
NASDAQ
22 Oct 14 15:20:02
$CYTX - Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment http://t.co/edgYCLOC38
The Fly
22 Oct 14 15:19:37
$CYTX Cytori Therapeutics receives FDA approval to resume ATHENA trial enrollment: Full Story http://t.co/7jjIlE7e81
				
				
By  +Follow August 1, 2013 8:43AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.